MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease | Zendy

PierreAntoine Juge | Zendy; Joyce Lee | Zendy; Esther Ebstein | Zendy; Hiroshi Furukawa | Zendy; Evgenia Dobrinskikh | Zendy; Steven Gazal | Zendy; Caroline Kannengiesser | Zendy; Sèbastien Ottaviani | Zendy; Shomi Oka | Zendy; Shigeto Tohma | Zendy; Naoyuki Tsuchiya | Zendy; Jorge RojasSerrano | Zendy; Montserrat I. González-Pérez | Zendy; Mayra Mejía | Zendy; Ivette BuendiaRoldán | Zendy; Ramcés FalfánValencia | Zendy; Enrique Ambrocio-Ortiz | Zendy; Effrosyni D. Manali | Zendy; Spyros A. Papiris | Zendy; T. Karageorgas | Zendy; Dimitrios T. Boumpas | Zendy; Katerina M. Antoniou | Zendy; Coline H.M. van Moorsel | Zendy; Joanne van der Vis | Zendy; Yaël A de Man | Zendy; Jan C. Grutters | Zendy; Yaping Wang | Zendy; Raphaël Borie | Zendy; Lidwine Wémeau-Stervinou | Zendy; B. Wallaert | Zendy; RenéMarc Flipo | Zendy; Hilario Nunès | Zendy; Dominique Valeyre | Zendy; Nathalie Saidenberg-Kermanac’h | Zendy; MarieChristophe Boissier | Zendy; S. MarchandAdam | Zendy; Aline Frazier | Zendy; Pascal Richette | Zendy; Yannick Allanore | Zendy; Jean Sibilia | Zendy; Claire Dromer | Zendy; Christophe Richez | Zendy; Thierry Schaeverbeke | Zendy; H. Lioté | Zendy; Gabriel Thabut | Zendy; Nadia Nathan | Zendy; Serge Amselem | Zendy; Martin Soubrier | Zendy; Vincent Cottin | Zendy; Annick Clément | Zendy; Kevin D. Deane | Zendy; Avram Walts | Zendy; Tasha E. Fingerlin | Zendy; Aryeh Fischer | Zendy; Jay H. Ryu | Zendy; Eric L. Matteson | Zendy; Timothy B. Niewold | Zendy; Deborah Assayag | Zendy; Andrew J. Gross | Zendy; Paul J. Wolters | Zendy; Marvin I. Schwarz | Zendy; Michael Holers | Zendy; Joshua J. Solomon | Zendy; Tracy J. Doyle | Zendy; Iván O. Rosas | Zendy; Cornelis Blauwendraat | Zendy; Mike A. Nalls | Zendy; MariePierre Debray | Zendy; Cathérine Boileau | Zendy; Bruno Crestani | Zendy; David A. Schwartz | Zendy; Philippe Dieudé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

Author(s) -

PierreAntoine Juge,

Joyce Lee,

Esther Ebstein,

Hiroshi Furukawa,

Evgenia Dobrinskikh,

Steven Gazal,

Caroline Kannengiesser,

Sèbastien Ottaviani,

Shomi Oka,

Shigeto Tohma,

Naoyuki Tsuchiya,

Jorge RojasSerrano,

Montserrat I. González-Pérez,

Mayra Mejía,

Ivette BuendiaRoldán,

Ramcés FalfánValencia,

Enrique Ambrocio-Ortiz,

Effrosyni D. Manali,

Spyros A. Papiris,

T. Karageorgas,

Dimitrios T. Boumpas,

Katerina M. Antoniou,

Coline H.M. van Moorsel,

Joanne van der Vis,

Yaël A de Man,

Jan C. Grutters,

Yaping Wang,

Raphaël Borie,

Lidwine Wémeau-Stervinou,

B. Wallaert,

RenéMarc Flipo,

Hilario Nunès,

Dominique Valeyre,

Nathalie Saidenberg-Kermanac’h,

MarieChristophe Boissier,

S. MarchandAdam,

Aline Frazier,

Pascal Richette,

Yannick Allanore,

Jean Sibilia,

Claire Dromer,

Christophe Richez,

Thierry Schaeverbeke,

H. Lioté,

Gabriel Thabut,

Nadia Nathan,

Serge Amselem,

Martin Soubrier,

Vincent Cottin,

Annick Clément,

Kevin D. Deane,

Avram Walts,

Tasha E. Fingerlin,

Aryeh Fischer,

Jay H. Ryu,

Eric L. Matteson,

Timothy B. Niewold,

Deborah Assayag,

Andrew J. Gross,

Paul J. Wolters,

Marvin I. Schwarz,

Michael Holers,

Joshua J. Solomon,

Tracy J. Doyle,

Iván O. Rosas,

Cornelis Blauwendraat,

Mike A. Nalls,

MariePierre Debray,

Cathérine Boileau,

Bruno Crestani,

David A. Schwartz,

Philippe Dieudé

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1801562

Subject(s) - rheumatoid arthritis , interstitial lung disease , medicine , disease , lung disease , lung , pathology , dermatology , immunology

Given the phenotypic similarities between rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research